New Cardiovascular Horizons digital symposium
Today, September 24th at 19:00 ET Philips will host a symposium entitled 'QuickClear Mechanical Thrombectomy System: A Powerfully Simple and Cost-Effective Solution' as part of the New Cardiovascular Horizons (NCVH) digital education series. To register, visit here.
The Philips QuickClear Mechanical Thrombectomy System is U.S. FDA 510(k) cleared and available for sale in the U.S., with future expansion of availability to other geographies planned.
[1] Testing performed in-house. Data on file.
[2] The Philips QuickClear mechanical thrombectomy system is indicated for the removal of soft, fresh emboli and thrombi from the vessels of the peripheral arterial and venous systems.
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries.
Back to HCB News
